Edition:
United States

Santen Pharmaceutical Co Ltd (4536.T)

4536.T on Tokyo Stock Exchange

1,675JPY
10:29pm EDT
Change (% chg)

¥5 (+0.30%)
Prev Close
¥1,670
Open
¥1,693
Day's High
¥1,697
Day's Low
¥1,668
Volume
1,133,500
Avg. Vol
1,843,445
52-wk High
¥1,758
52-wk Low
¥1,251

Latest Key Developments (Source: Significant Developments)

Santen Pharmaceutical to retire treasury shares
Wednesday, 14 Dec 2016 02:10am EST 

Santen Pharmaceutical Co Ltd <4536.T>: Says it to retire 8,300,000 shares (2 percent stake) of its common stock on Dec. 29 .Says the total shares outstanding will be 406,005,015 shares after the retirement.  Full Article

Santen Pharmaceutical unit sets up pharmaceutical JV in China
Tuesday, 30 Aug 2016 03:13am EDT 

Santen Pharmaceutical Co Ltd <4536.T>: Says its China-based unit set up a JV in Chongqing, China, with a China-based company, Cory Pharmaceutical Co., LTD . Says the JV is capitalized at 200 million yuan .Says the unit is holding 49 percent stake in the JV.  Full Article

SANTEN PHARMACEUTICAL raises year-end dividend forecast for FY 2016
Tuesday, 23 Feb 2016 02:00am EST 

SANTEN PHARMACEUTICAL CO LTD:Raised year-end dividend forecast to 13 yen per share from 12 yen per share for FY ending March 2016.  Full Article

SANTEN PHARMACEUTICAL assigns anti-rheumatic pharmaceuticals business to Hyperion Pharma
Monday, 3 Aug 2015 03:00am EDT 

SANTEN PHARMACEUTICAL CO LTD:Assigned its anti-rheumatic pharmaceuticals business to Hyperion Pharma, under a simplified company-split method, effective Aug. 3.  Full Article

SANTEN PHARMACEUTICAL announces assignment of anti-rheumatic pharmaceuticals business to Hyperion Pharma
Tuesday, 12 May 2015 02:20am EDT 

SANTEN PHARMACEUTICAL CO LTD:To enter an agreement with Showa Yakuhin Kakou Co., Ltd. and Hyperion Pharma Co., Ltd. to assign its anti-rheumatic pharmaceuticals business to Hyperion Pharma, under a simplified company-split method, effective Aug. 3.To receive 45 bln yen in cash from Hyperion Pharma.After completion of the assignment, Showa Yakuhin intends to merge its pharmaceutical business with the anti-rheumatic pharmaceuticals business succeeded by Hyperion Pharma.  Full Article

R-Tech Ueno to acquire development and business right of ophthalmic from SANTEN PHARMACEUTICAL
Monday, 27 Apr 2015 02:30am EDT 

R-Tech Ueno Ltd:To acquire development and business right of ophthalmic named DE-105 from SANTEN PHARMACEUTICAL CO LTD.DE-105 is used for treatment of persistent corneal epithelial defect.  Full Article

More From Around the Web

BRIEF-Santen Pharmaceutical repurchases shares at 12.31 bln yen

* Says it repurchased 8,284,000 shares of its common stock, at the price of 12.31 billion yen in total, as of Nov. 22